英夫利西单抗治疗克罗恩病的疗效及安全性分析  

Efficacy and Safety Analysis of Infliximab in the Treatment of Crohn's Disease

作　　者：周培[1] 沈玉婷 沈卫东[1] ZHOU Pei;SHEN Yuting;SHEN Weidong(Department of Gastroenterology,Jiangyin People's Hospital,Jiangyin,Jiangsu Province,214400 China)

机构地区：[1]江阴市人民医院消化内科,江苏江阴214400

出　　处：《系统医学》2023年第3期119-122,共4页Systems Medicine

基　　金：无锡市卫健委青年项目(Q202155)。

摘　　要：目的探讨对克罗恩病患者实施英夫利西单抗治疗后的临床疗效以及安全性。方法选取2018年1月—2021年10月江阴市人民医院收治的82例克罗恩病患者进行研究。随机分为常规组(在传统治疗基础上,选择硫唑嘌呤进行治疗)和研究组(在常规组治疗基础上,选择英夫利西单抗进行治疗),各41例。治疗后,比较两组患者临床治疗总有效率、并发症总发生率、血清指标变化、主观症状评分、内镜下CD严重度指数(CDEIS)评分以及CD活动指数(CDAI)评分,并且监测应用英夫利西单抗治疗期间所出现的药物不良反应。结果研究组疾病治疗总有效率(95.12%)高于常规组(73.17%),差异有统计学意义(χ^(2)=7.404,P<0.05)。研究组并发症总发生率(9.76%)低于常规组(26.83%),差异有统计学意义(P<0.05)。治疗前,两组TP(血清总蛋白)、CRP(C反应蛋白)、ESR(血细胞沉降率)、ALB(白蛋白)对比,差异无统计学意义(P>0.05);治疗后,研究组TP以及ALB水平均高于常规组,CRP以及ESR水平均低于常规组,差异有统计学意义(P<0.05)。治疗前,两组主观症状评分、CDEIS评分以及CDAI评分对比,差异无统计学意义(P>0.05);治疗后,研究组主观症状评分、CDEIS评分以及CDAI评分均低于常规组,差异有统计学意义(P<0.05)。应用英夫利西单抗治疗期间,共有5例患者出现不良反应,对症处理后均在短期内好转。结论英夫利西单抗应用于克罗恩病患者能有效减少肠梗阻、大量便血、瘘管、腹腔脓肿等并发症,促进肠道黏膜炎症修复,改善血清学指标以及患者主观症状,从而改善本病预后,药物安全性高。Objective To investigate the clinical efficacy as well as safety obtained after the implementation of infliximab treatment in patients with Crohn's disease.Methods 82 patients with Crohn's disease admitted to Jiangyin People's Hospital from January 2018 to October 2021 were selected for study.They were randomly divided into the conventional group(on the basis of traditional treatment,azathioprine was selected for treatment)and the study group(on the basis of conventional treatment,infliximab was selected for treatment),with 41 cases each.After treatment,the total effective rate of clinical treatment,total incidence of complications,changes in serum indicators,subjective symptom score,endoscopic CD severity index(CDEIS)score and CD activity index(CDAI)score of the two groups were compared,and the adverse drug reactions during the treatment with infliximab were monitored.Results The total effective rate of disease treatment in the study group(95.12%)was higher than that in the conventional group(73.17%),and the difference was statistically significant(χ^(2)=7.404,P<0.05).The total incidence of complications in the study group(9.76%)was lower than that in the conventional group(26.83%),and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in total protein(TLB),C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),albumin(ALB)between the two groups(P>0.05);after treatment,the levels of(TP)and ALB in the study group were higher than those in the conventional group,and the levels of CRP and ESR were lower than those in the conventional group,and the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in subjective symptom score,CDEIS score and CDAI score between the two groups(P>0.05);after treatment,the subjective symptom score,CDEIS score and CDAI score of the study group were lower than those of the conventional group,and the difference was statistically significant(P<0.05).During the treatm

关 键 词：英夫利西单抗 克罗恩病 治疗总有效率 并发症 黏膜炎症修复 血清指标变化 主观症状评分 CDEIS评分 CDAI评分 

分 类 号：R521[医药卫生—内科学]